Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amgen (NQ:AMGN)

265.86 -6.19 (-2.28%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amgen

< Previous 1 2
...
23 24 25 26 27 28 29 30 31
...
53 54 Next >
Is AbbVie or Amgen the Better Bargain Buy Right Now?
These elite drugmakers are both working through a number of headwinds. 
Via The Motley Fool
ASCO 2023 – Claudin 6 Makes A Splash In Ovarian Cancer
This year’s 2023 American Society of Clinical Oncology Annual Meeting (ASCO 2023) provided a surprising amount of clinical data relevant to biopharma investors. 
Via Benzinga
Wall Street's Most Accurate Analysts Say Hold These 3 Health Care Stocks With Over 3% Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high... 
Via Benzinga
The 3 Best Long-Term Dividend Stocks to Buy in June
Build a solid investment portfolio with the best long-term dividend stocks and enjoy passive income for many years to come. 
Via InvestorPlace
Dow Stocks Like Microsoft, Apple, Disney, and Verizon Reveal Two Sides of the Market
Many well-known stocks are missing out on the market's epic 2023 rally. 
Via The Motley Fool
Here's How Much $1000 Invested In Amgen 15 Years Ago Would Be Worth Today
Via Benzinga
Amgen Unusual Options Activity For June 01
Via Benzinga
Why AbbVie and Amgen Are Moving Lower Today
An ultra-low-priced biosimilar may negatively impact both biotechs. 
Via The Motley Fool
The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree
Big Pharma is facing a patent cliff that could siphon off billions in revenue. 
Via Investor's Business Daily
3 Undervalued Biotech Stocks to Buy Before They Blast Off
Fundamental analysis makes these three undervalued biotech stocks to buy plus they have other catalysts that make them compelling. 
Via InvestorPlace
Is Amgen a Good Dividend Stock?
The biotech's yield is near an all-time high right now. 
Via The Motley Fool
3 Stocks Worth Buying at 52-Week Lows
Here are three stocks that are trading near their 52-week lows and may be primed for a short-term rally for opportunistic investors 
Via MarketBeat
Check Out What Whales Are Doing With AMGN
Via Benzinga
Amgen's Debt Overview
Via Benzinga
Here's How Much You Would Have Made Owning Amgen Stock In The Last 15 Years
Via Benzinga
3 Safe Dividend Stocks to Beat Inflation
Look for businesses that thrive in any economic environment. 
Via The Motley Fool
Top-Ranked Dividend Stocks: A Smarter Way To Boost Your Retirement Income
Here are three dividend-paying stocks retirees should consider for their nest egg portfolio. 
Via Talk Markets
A Challenger to J&J's Top Blockbuster Is on the Way. Here's What You Need to Know.
Biotech-giant Amgen aims to launch a rival. 
Via The Motley Fool
3 Dogs of the Dow for High-Yield Investors
These Dogs of the Dow boast high dividend yields and will hold up well in a potential recession. Let's take a look. 
Via InvestorPlace
FTC Wants to Block the Amgen-Horizon Deal: Is Pfizer's Acquisition of Seagen at Risk, Too?
Should Pfizer and Seagen investors be worried? 
Via The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
The Important — And Overlooked — Caveat Behind Pfizer's Rival To Novo Nordisk In Diabetes
Pfizer stock surged on its diabetes news this week, but one analyst says there's a key piece missing from the story. 
Via Investor's Business Daily
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Pfizer Stock Jumps After Diabetes Drug Tops Ozempic In Weight Loss
Pfizer's diabetes drug led to faster weight loss than Novo Nordisk's Ozempic. 
Via Investor's Business Daily
Stock Market Rally Hits 2023 Highs As Big Techs Lead; Tesla, Walmart, On Holding In Focus: Weekly Review
Chips, software and AI plays were strong. But leadership remains narrow. 
Via Investor's Business Daily
Is Pfizer's Seagen Deal In Jeopardy Amid Antitrust Scrutiny?
Despite worries about FTC scrutiny, Pfizer remains optimistic about its planned Seagen acquisition, issuing $31 billion in bonds to finance the deal. 
Via MarketBeat
Topics Bonds
Exposures Debt Markets
The FTC, Amgen, And Horizon: A New Hurdle For Biotech Deal Making Or Regulatory Overreach?
The FTC suit against Amgen appears to be a clear case of regulatory overreach but what this ultimately means will take time to fully develop. 
Via Talk Markets
Vertex Pharmaceuticals Hits Record High on Strong Q1 Earnings
Vertex Pharmaceuticals hits record high on strong earnings, FDA approval for cystic fibrosis medication for infants. Analysts recently boosted price targets. 
Via MarketBeat
Exposures Product Safety
TScan Therapeutics Shares Fall After Preliminary Data Highlight In Leukemia Patients
TScan Therapeutics Inc (NASDAQ: TCRX) announced a poster presentation highlighting preliminary data from the Phase 1 umbrella clinical trial evaluating TSC-100 and TSC-101 targeting minor... 
Via Benzinga
FDA Signals Support For Pfizer's Maternal RSV Shot Ahead Of Adcomm, Pfizer Raises $31B In Debt To Fund Seagen Deal
Pfizer Inc (NYSE: PFE) plans to raise $31 billion from a debt offering to finance its proposed acquisition of Seagen Inc (NASDAQ: SGEN)  
Via Benzinga
< Previous 1 2
...
23 24 25 26 27 28 29 30 31
...
53 54 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback